Wealthfront Advisers LLC Raises Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Wealthfront Advisers LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,268 shares of the medical research company’s stock after acquiring an additional 4,145 shares during the quarter. Wealthfront Advisers LLC’s holdings in Thermo Fisher Scientific were worth $15,861,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $28,000. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Finally, Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Barclays dropped their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. DZ Bank began coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Finally, HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $602.14.

Thermo Fisher Scientific Price Performance

TMO opened at $544.03 on Friday. The firm has a market cap of $202.17 billion, a PE ratio of 29.91, a P/E/G ratio of 2.37 and a beta of 0.87. The stock has a 50-day moving average price of $483.22 and a 200-day moving average price of $514.76. Thermo Fisher Scientific Inc. has a 1 year low of $403.36 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.